Maintenance Therapy

Maintenance Therapy

Maintenance therapy is a treatment paradigm widely used in chronic disease management, where ongoing pharmacological intervention is required to sustain the clinical benefits achieved during an initial induction or dose-escalation phase. In the context of obesity, maintenance therapy refers to the continued use of anti-obesity medication after the weight loss phase to prevent weight regain. This approach recognizes obesity as a chronic, relapsing condition with persistent pathophysiology that does not resolve with temporary treatment, analogous to chronic conditions like hypertension or type 2 diabetes that require long-term pharmacotherapy.

The rationale for maintenance therapy in obesity is grounded in the biology of energy homeostasis. After weight loss, metabolic adaptation and hormonal counter-regulation create a strong physiological drive toward weight regain. Continued pharmacotherapy helps counteract these compensatory mechanisms by maintaining appetite suppression, preserving improvements in metabolic rate, and sustaining the beneficial hormonal environment created during active treatment. Clinical evidence from the incretin therapy class has consistently demonstrated that discontinuing treatment leads to substantial weight regain, reinforcing the need for long-term treatment strategies.

For retatrutide, maintenance therapy considerations are particularly relevant given the unprecedented magnitude of weight loss observed in Phase 2 trials. Questions under active investigation include whether a lower maintenance dose can preserve weight loss achieved during dose escalation, whether periodic treatment cycles could be effective, and what the optimal duration of continuous therapy should be. The Phase 3 TRIUMPH program is expected to provide data on long-term treatment durability, and future trial designs may specifically evaluate step-down dosing protocols that balance sustained efficacy with minimized drug exposure and cost.